AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04632940
Drug: Pamrevlumab
RxNorm normalized name: Pamrevlumab
DrugBank: Pamrevlumab (DB14952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamrevlumab will be administered per dose and schedule specified in the arm description.
Trial: NCT05257265
Drug: Centanafadine Hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Centanafadine (DB14841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT00001100
Drug: ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05148884
Drug: NLX-112
RxNorm normalized name: NLX-101
DrugBank: F-15599 (DB16936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLX-112 will be supplied as tablets containing 0.25 mg NLX-112. NLX-112 is a structurally novel centrally acting, high-efficacy selective 5-HT1A receptor agonist with nanomolar affinity for 5-HT1A receptors. Proposed as a treatment for L-DOPA-induced-dyskinesia in Parkinson's disease.
Trial: NCT05334108
Drug: Ecopipam
RxNorm normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ecopipam HCl \~2mg/kg/day
Trial: NCT05334108
Drug: Cohort 2 Probe Substrate
RxNorm normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupropion
Trial: NCT05278156
Drug: CPL500036 - low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
Trial: NCT05278156
Drug: CPL500036 - high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.
Trial: NCT06368726
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone Risperidone according to child's weighs
Trial: NCT05028803
Drug: sodium phenylbutyrate
RxNorm normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same as arm/group
Trial: NCT04787744
Drug: Goserelin, Histrelin, Leuprolide & Triptorelin
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) using an LHRH agonist
Trial: NCT04787744
Drug: ADT + Nilutamide, Flutamide, & Bicalutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ADT adding anti-androgen therapy to an LHRH agonist
Trial: NCT04787744
Drug: Degarelix & Relugolix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ADT using an LHRH Antagonist.
Trial: NCT04787744
Drug: ADT + Docetaxel +/- prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enhanced SST using chemohormonal therapy
Trial: NCT04787744
Drug: ADT + Abiraterone + Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enhanced SST using Abiraterone + Prednisone
Trial: NCT04787744
Drug: ADT + Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Enhanced SST using ADT + Apalutamide
Trial: NCT04787744
Drug: ADT + Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enhanced SST using ADT + Enzalutamide
Trial: NCT06147232
Drug: Sotagliflozin
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Sodium-glucose-co-transporter 1 and 2 inhibitor
Trial: NCT05424393
Drug: YISAIPU® ( An etanercept biosimilar)
DrugBank: Yisaipu (DB17076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YISAIPU®, an etanercept biosimilar produced by 3SBio Inc., is a TNF-α inhibitor targeting soluble TNF-α to inhibit its interaction with cell-surface receptors. It has been widely used in clinical practice for 17 years in China. According to the prescription information, YISAIPU should be given as 25mg, biw, pc.
Trial: NCT04996056
Drug: TNX-1300
RxNorm normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNX 1300 200 mg Intravenous injection
Trial: NCT05051956
Drug: Palbociclib 125mg and Ribociclib 600 mg
RxNorm normalized name: palbociclib 125 MG
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of Palbociclib or Ribociclib
Trial: NCT06536010
Drug: Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VAG in the induction phase of the ND-AML treatment protocol
Trial: NCT00000838
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00000838
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000838
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000838
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04399382
Drug: Biologics
RxNorm normalized name: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection
DrugBank: COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection (DB16520)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The exposure of interest in this observational study is the biological therapy of Tumor Necrosis Factor (TNF) inhibitor, specifically etanercept biosmilar/ infliximab/ adalimumab/ golimumab.
Trial: NCT00000855
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05759884
Drug: Anti-VEGF
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreous injection of anti-VEGF drugs
Trial: NCT05684640
Drug: Rodatristat Ethyl
RxNorm normalized name: Rodatristat ethyl
DrugBank: Rodatristat ethyl (DB18479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 600mg, QD
Trial: NCT00061256
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00061256
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00061256
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04795479
Drug: Relacorilant
RxNorm normalized name: Relacorilant
DrugBank: Relacorilant (DB14976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relacorilant 400 mg (therapeutic dose) or 800 mg (supra-therapeutic dose) capsule by mouth once daily
Trial: NCT04795479
Drug: Placebo to relacorilant
DrugBank: Relacorilant (DB14976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to relacorilant capsule by mouth once daily
Trial: NCT04795479
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg tablet by mouth
Trial: NCT06231017
Drug: Adebrelimab + Cetuximab+ Chemotherapy
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adebrelimab:1200 mg, D1, Q2W+Cetuximab:500 mg, D1, Q2W+FOLFOX6(Q2W) or FOLFIRI(Q2W) until PD or resectability or to max 12 cycles
Trial: NCT05934214
Drug: Immune checkpoint inhibitor
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reports associated with an an Immune checkpoint inhibitor with a status of Suspect or Interacting~ICI will include the following list of FDA-apporved ICIs:~nivolumab, pembrolizumab, cemiplimab, dostarlimab, durvalumab, atezolizumab, avelumab, ipilimumab, tremelimumab, relatlimab
Trial: NCT06290128
Drug: Riliprubart
RxNorm normalized name: Riliprubart
DrugBank: Riliprubart (DB18355)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Route of administration: IV Infusion
Trial: NCT06290128
Drug: Riliprubart
RxNorm normalized name: Riliprubart
DrugBank: Riliprubart (DB18355)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Route of administration: SC Injection
Trial: NCT05757791
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The full duration of therapy will be six-weeks. The route of administration will be oral. The starting dose of the medication will be 10mg daily for the first 14 days of the study, with a dose escalation to 25mg for the last 28 days of the study.
Trial: NCT06098599
Drug: Doxorubicin hydrochloride liposome injection
RxNorm normalized name: doxorubicin hydrochloride liposome Injection
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin hydrochloride liposome injection was administered intravenously for 90min (±3min) with an infusion pump on day 1 and day 29 of the trial. Doxorubicin hydrochloride liposome injection was diluted with 250mL 5% glucose injection.
Trial: NCT06662721
Drug: Baricitinib 4 MG
RxNorm normalized name: baricitinib 4 MG
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The patients received Baricitinib for 48 weeks. The method is to take Baricitinib 4mg every day for a period of 48 weeks. All the patients will be followed up prospectively for 48 weeks.
Trial: NCT05888532
Drug: Copper-64 labeled Granzyme B (64Cu-GRIP B)
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV prior to imaging
Trial: NCT06667167
Drug: Induction Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction phase of carboplatin+etoposide+pembrolizumab followed by maintenance of Pembrolizumab+sacituzumab govitecan
Trial: NCT06594783
Drug: Carvedilol alone
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).
Trial: NCT05023031
Drug: NVP-2102
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet formulation for oral administration, single dose of NVP-2102 at Day 1
Trial: NCT04608214
Drug: Alisporivir
RxNorm normalized name: Alisporivir
DrugBank: Alisporivir (DB12139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of alisporivir at the dose of 600 mg p.o. BID from D1 to D14 to patients and standard of care (SOC).
Trial: NCT06610526
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin by oral administration
Trial: NCT06669663
Drug: Pimonidazole hydrochloride (Hypoxyprobe™-1)
RxNorm normalized name: chloroprocaine
DrugBank: Pimonidazole (DB12485)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Pimonidazole (non-CTIMP) prior to their surgery for OG cancer and then undergo intra-operative sampling.
Trial: NCT06670963
Drug: EPO
RxNorm normalized name: Epo B
DrugBank: Patupilone (DB03010)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 50 units/kg IV 3 times weekly
Trial: NCT05687266
Drug: Datopotamab deruxtecan
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
Trial: NCT05687266
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
Trial: NCT05687266
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
Trial: NCT05687266
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle for a maximum of 35 cycles or 2 years (whichever occurs first).
Trial: NCT05687266
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
Trial: NCT05687266
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Trial: NCT05687266
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
Trial: NCT05728814
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The treatment under observation is dostarlimab administered on day 1 of each treatment cycle until disease progression, unacceptable toxicity or patient/doctor's decision.~The recommended dose for dostarlimab is 4 cycles of 500 mg every 3 weeks followed by 1000 mg every 6 weeks for all subsequent cycles.
Trial: NCT05827159
Drug: Naltrexone Pill
RxNorm normalized name: naltrexone Pill
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the MAUD component, some participants will receive oral Naltrexone in the ED.
Trial: NCT05827159
Drug: Naltrexone Injection
RxNorm normalized name: naltrexone Injection
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the MAUD component, some participants will receive a dose of XR-NTX (injection) in the ED.
Trial: NCT06310005
Drug: BI 3006337
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 3006337
Trial: NCT05453929
Drug: Rocuronium for deep NMB
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
Trial: NCT05453929
Drug: Rocuronium for moderate NMB
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
Trial: NCT05827159
Drug: Gabapentin Pill
RxNorm normalized name: gabapentin Pill
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the MAUD component, ancillary treatment with gabapentin will be provided.
Trial: NCT05699148
Drug: Elexacaftor / Ivacaftor / Tezacaftor
RxNorm normalized name: elexacaftor / ivacaftor / tezacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Triple combination therapy is licensed in the UK for prescription to paediatric patients aged 6 to 11 years. ETI will be started as part of routine clinical care.
Trial: NCT00002113
Drug: Flucytosine
RxNorm normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002113
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01634373
Drug: Torrent's Quetiapine Fumarate Tablets
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06063473
Drug: Trifarotene Cream 0.005%
DrugBank: Trifarotene (DB12808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
Trial: NCT04729751
Drug: Maralixibat
RxNorm normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL)~* 400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base~* 600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base
Trial: NCT05535166
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Route of administration: Intravenously (IV)
Trial: NCT05535166
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Route of administration: Intravenously (IV)
Trial: NCT05535166
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of administration: Intravenously (IV)
Trial: NCT06611891
Drug: 68Ga-DOTATOC
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow direct intravenous injection
Trial: NCT06612268
Drug: Etavopivat
RxNorm normalized name: Etavopivat
DrugBank: Etavopivat (DB18176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etavopivat will be administered orally.
Trial: NCT05100706
Drug: Continuous adductor canal block (CACB)
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% infusion through adductor canal catheter
Trial: NCT05741294
Drug: Tirbanibulin 2.5 mg ointment
DrugBank: Tirbanibulin (DB06137)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm\^2) of the face or scalp.
Trial: NCT05592223
Drug: BCG Vaccine USP
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x10\^6 cfu Tice® BCG (ID)
Trial: NCT05592223
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INH in the dose of 300 mg for three days post BCG injection.
Trial: NCT05592223
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIF in the dose of 600 mg for seven days post BCG injection.
Trial: NCT05535166
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Route of administration: Intravenously (IV)
Trial: NCT05535166
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of administration: Intravenously (IV)
Trial: NCT05535166
Drug: Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Route of administration: subcutaneous (SQ)
Trial: NCT05535166
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Route of administration: subcutaneous (SQ) or Intravenously (IV)
Trial: NCT05397236
Drug: Bupivacaine- Magnesium
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received QL block with 20 ml of 0.25% bupivacaine (2, 4)plus 5 ml of 10% MgSO4.
Trial: NCT05397236
Drug: Bupivacaine dexamethasone
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 2 ml of 8 mg dexamethasone plus 3 ml of 0.9% NS.
Trial: NCT05397236
Drug: Bupivacaine saline
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 5 ml of 0.9% NS.
Trial: NCT04736810
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04736810
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT04736810
Drug: Anlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06608914
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
Trial: NCT06608914
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
Trial: NCT05573802
Drug: Belantamab Mafodotin-Blmf
RxNorm normalized name: belantamab mafodotin-blmf
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes.
Trial: NCT05573802
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be administered per os.
Trial: NCT05573802
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be administered intravenously or per os.
Trial: NCT05573802
Drug: Nirogacestat
RxNorm normalized name: NIROGACESTAT
DrugBank: Nirogacestat (DB12005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nirogacestat will be administrated each day for all subsequent cycles were Blmf is also administrated.